These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 27019798)
1. Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight. Bugaj AM World J Methodol; 2016 Mar; 6(1):65-76. PubMed ID: 27019798 [TBL] [Abstract][Full Text] [Related]
2. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764 [TBL] [Abstract][Full Text] [Related]
3. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929 [TBL] [Abstract][Full Text] [Related]
4. Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies. Nogueira L; Tracey AT; Alvim R; Reisz P; Scherz A; Coleman JA; Kim K Molecules; 2020 Nov; 25(22):. PubMed ID: 33228126 [TBL] [Abstract][Full Text] [Related]
5. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy. Flegar L; Buerk B; Proschmann R; Propping S; Groeben C; Baunacke M; Herout R; Huber J; Thomas C; Borkowetz A Eur Urol Focus; 2022 Jan; 8(1):121-127. PubMed ID: 33602642 [TBL] [Abstract][Full Text] [Related]
6. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587 [TBL] [Abstract][Full Text] [Related]
7. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment. Chelly S; Maulaz P; Bigot P; Azzouzi AR; Lebdai S Asian J Androl; 2020; 22(5):454-458. PubMed ID: 31939351 [TBL] [Abstract][Full Text] [Related]
8. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study. Rodriguez-Rivera JA; Rodriguez-Lay R; Zegarra-Montes L; Benzaghou F; Gaillac B; Azzouzi AR; Reis LO; Palma P Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):632-638. PubMed ID: 29699883 [TBL] [Abstract][Full Text] [Related]
19. Follow-up of vascular-targeted photodynamic therapy in a real-world setting. Borkowetz A; Kwe J; Boehm K; Baunacke M; Herout R; Lucke M; Burcea A; Thomas C World J Urol; 2024 Jan; 42(1):55. PubMed ID: 38244089 [TBL] [Abstract][Full Text] [Related]